Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 17/20 | 0.67 |
| ▸ | WDR77 | Q9BQA1 | 5/20 | 0.67 |
| ▸ | AHCY | P23526 | 1/20 | 0.65 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.65 |
| ▸ | METTL3 | Q86U44 | 3/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29325375 | 1.00 | PRMT5 (0.67) | PRMT5WDR77AHCYADORA2BMETTL3 | |
| SCHEMBL18571689 | 1.00 | PRMT5 (0.67) | PRMT5WDR77AHCYADORA2BMETTL3 | |
| SCHEMBL29323387 | 1.00 | PRMT5 (0.67) | PRMT5WDR77AHCYADORA2BMETTL3 | |
| SCHEMBL9281381 | 0.90 | PRMT5 (0.67) | PRMT5WDR77METTL3 | |
| SCHEMBL9109059 | 0.90 | PRMT5 (0.67) | PRMT5WDR77METTL3 | |
| SCHEMBL25956773 | 0.87 | PRMT5 (0.69) | PRMT5WDR77METTL3 | |
| SCHEMBL18922569 | 0.86 | PRMT5 (0.62) | PRMT5WDR77METTL3 | |
| SCHEMBL18572585 | 0.85 | AHCY (0.52) | PRMT5WDR77AHCYADORA2B | |
| SCHEMBL22002025 | 0.85 | AHCY (0.52) | PRMT5WDR77AHCYADORA2B | |
| SCHEMBL10186262 | 0.85 | AHCY (0.52) | PRMT5WDR77AHCYADORA2BMETTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238323-A1 | MODIFIED NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS FOR CORONA AND OTHER VIRUSES | EMORY UNIVERSITY | 2024-07-18 | — | — | US | disclosed |
| US-20230146410-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | JANSSEN BIOTECH INC (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230146410-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | JANSSEN BIOTECH INC (US) | 2023-05-11 | — | — | US | disclosed |
| EP-3573718-B1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | JANSSEN BIOTECH INC (US) | 2022-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238323-A1 | MODIFIED NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS FOR CORONA AND OTHER VIRUSES | MTAP, PNP, SARS1 | PRMT5 1177/4885WDR77 2568/4885AHCY 804/4885 |
| US-20230146410-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | STING1, CGAS, MAVS | PRMT5 1272/4885WDR77 1247/4885AHCY 2705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.